NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological...
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate...
Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and CEO, will present the phase 3...
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological...
Canaccord Genuity analyst John Newman maintained a Buy rating on Candel Therapeutics yesterday and set a price target of $25.00. The company’s shares closed yesterday at $5.78.Elevate Your Investing...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Candel Therapeutics (CADL – Research Report) and Gain Therapeutics (GANX – Research Report) with bullish...
Candel Therapeutics (CADL) announced interim data from its ongoing phase 1b clinical trial of CAN-3110 in recurrent glioblastoma, and a publication in the high-impact scientific journal Science Translational...
$50 million drawn down at closing, with access to up to an additional $80 million Strengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell...
PHOENIX , Oct. 14, 2025 /PRNewswire/ -- Trinity Capital Inc. Â (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $130 million in growth capital...